NASDAQ$COO

The Cooper Companies Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Revenue increased driven by CooperVision and CooperSurgical, but EPS decreased.

CooperCompanies reported a 6% increase in revenue to $877.4 million, with CooperVision and CooperSurgical showing growth. However, GAAP diluted EPS decreased by 69% to $0.80, while non-GAAP diluted EPS decreased by 5% to $3.08.

  • Revenue increased 6% year-over-year to $877.4 million.
  • CooperVision revenue was up 6% to $589.3 million.
  • CooperSurgical revenue was up 4% to $288.1 million.
  • GAAP diluted earnings per share (EPS) decreased 69% to $0.80.

Headline financials

Total Revenue

$877M

Previous: $830M+5.7%
EPS (adj)

$0.77

Previous: $0.81-4.9%
GAAP Gross Margin

66.0%

Previous: 64.0%+3.1%
GAAP Operating Margin

11.0%

Previous: 16.0%-31.3%
Capital Expenditures

-$157M

Previous: -$101M-55.8%
Free Cash Flow

$134M

Previous: $197M-32.0%
Net Income

$39.8M

Previous: $127M-68.6%
Operating Income

$96.3M

Previous: $133M-27.4%
Gross Profit

$583M

Previous: $533M+9.5%
Cash & Equivalents

$112M

Previous: $399M-72.0%
Total Assets

$11.5B

Previous: $11.8B-2.0%

Revenue & EPS history

Cooper · Revenue · Quarterly

$877M

Q2 2023+5.7%vs Q2 2022
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

Cooper · $288M total across 2 segments · Q2 2023

  • Office and Surgical
    $163M+0.9%
  • Fertility
    $125M+9.4%

Forward guidance

The Company updated its fiscal year 2023 financial guidance.

Tailwinds

  • Fiscal 2023 total revenue of $3,512 - $3,569 million (organic growth of 7% to 9%)
  • CVI revenue of $2,365 - $2,400 million (organic growth of 8% to 10%)
  • CSI revenue of $1,147 - $1,169 million (organic growth of 5% to 7%)
  • Fiscal 2023 non-GAAP diluted earnings per share of $12.66 - $12.96
  • Fiscal year 2023 guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+0.5%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.1%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+12.1%

Q3 2024

Best reaction

-12.8%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.6%-8.0%-12.5%
Q4 2025-4.3%+4.8%+5.3%
Q3 2025-12.8%-11.8%-8.9%
Q2 2025+0.0%-0.3%+3.6%
Q1 2025-6.6%-13.1%-18.9%
Q4 2024-6.0%-5.6%-12.6%
Q3 2024+12.1%+12.1%+16.4%
Q2 2024+3.5%+3.8%-4.2%
Q1 2024+8.1%+7.3%+7.4%
Q4 2023-2.2%-0.7%+6.8%
Q3 2023-2.1%-3.5%-15.9%
Q2 2023-4.0%-5.1%+3.2%
Q1 2023+8.7%+3.9%+15.4%
Q4 2022-1.6%+4.8%+9.7%
Q3 2022+4.1%+2.5%-8.5%
Q2 2022-0.3%+1.3%-7.2%
Q1 2022+2.1%-8.5%+3.1%
Q4 2021+4.8%+8.7%+12.2%
Q3 2021+1.1%-0.7%-7.6%
Q2 2021-0.7%-3.2%+6.0%
Q1 2021+1.8%+0.3%+1.1%
Q4 2020+3.3%+3.3%+8.6%
Q3 2020+2.0%+0.3%+5.7%
Q2 2020-0.2%-5.0%-9.1%
Q1 2020-1.3%-0.9%-17.3%
Q4 2019-1.6%-2.4%+3.3%
Q3 2019-3.5%-6.7%-8.3%
Q2 2019+4.5%+9.0%+18.2%
Q1 2019-1.8%+0.1%+1.0%
Q4 2018-11.6%-7.3%-10.4%
Q3 2018-3.7%-3.4%+4.3%
Q2 2018+1.4%-0.4%+6.0%
Q1 2018+2.1%-3.8%-11.5%
Q4 2017-3.2%-1.9%-1.5%
Q3 2017-4.0%-2.5%-3.7%
Q2 2017+8.9%+10.5%+9.4%
Q1 2017-3.1%-3.6%-0.4%
Q4 2016+1.3%+4.1%+5.2%
Q3 2016+0.0%+1.3%-3.6%
Q2 2016-0.1%-0.4%+7.1%
Q1 2016+6.4%
Q4 2015-12.8%
Q3 2015-7.1%
Q2 2015-5.1%
Q1 2015+9.7%
Q4 2014-4.4%
Q3 2014+0.7%
Q2 2014+1.7%
Q1 2014+4.3%
Q4 2013-4.6%
Q3 2013-1.8%
Q2 2013+8.1%
Q1 2013+2.5%
Q4 2012+1.0%
Q3 2012+10.3%
Q2 2012-4.1%
Q1 2012+2.8%
Q4 2008+2.8%
Q4 2011+2.8%
Q3 2011-1.8%
Q2 2011+1.4%
Q2 2010+1.4%
Q1 2010+8.9%
Q1 2011+1.0%
Q4 2010-1.5%
Q3 2010+5.8%
Q3 2009+5.8%
Q4 2009+5.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro